These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27845591)

  • 1. Drug-target interaction kinetics: underutilized in drug optimization?
    Copeland RA
    Future Med Chem; 2016 Dec; 8(18):2173-2175. PubMed ID: 27845591
    [No Abstract]   [Full Text] [Related]  

  • 2. The importance of drug-target residence time.
    Zhang R; Monsma F
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):488-96. PubMed ID: 19562645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug target residence time: a misleading concept.
    Folmer RHA
    Drug Discov Today; 2018 Jan; 23(1):12-16. PubMed ID: 28782685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Kinetic Component in Drug Discovery: Using the Most Basic Pharmacological Concepts to Advance in Selecting Drugs to Combat CNS Diseases.
    Franco R; Castelló J; Canela EI
    Curr Neuropharmacol; 2020; 18(3):250-257. PubMed ID: 31573886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization.
    Peters SA; Ungell AL; Dolgos H
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):509-18. PubMed ID: 19562647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High performance enzyme kinetics of turnover, activation and inhibition for translational drug discovery.
    Zhang R; Wong K
    Expert Opin Drug Discov; 2017 Jan; 12(1):17-37. PubMed ID: 27784173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Equilibrium Models of Drug-Receptor Interactions Derived from Target-Mediated Drug Disposition.
    Peletier LA; Gabrielsson J
    AAPS J; 2018 May; 20(4):69. PubMed ID: 29761231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The link between pharmacodynamics and physiologically based pharmacokinetic models.
    Perera V; Elmeliegy MA; Rao G; Forrest A
    Clin Pharmacol Ther; 2013 Feb; 93(2):151-2. PubMed ID: 23299648
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to "The link between pharmacodynamics and physiologically based pharmacokinetic models".
    Rostami-Hodjegan A
    Clin Pharmacol Ther; 2013 Feb; 93(2):152. PubMed ID: 23281422
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacology in cerebrovascular disease research: Pharmacokinetics-pharmacodynamics to the rescue.
    Feuerstein GZ
    J Cereb Blood Flow Metab; 2016 Mar; 36(3):639-44. PubMed ID: 26661248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies.
    Bauer RA
    Drug Discov Today; 2015 Sep; 20(9):1061-73. PubMed ID: 26002380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives.
    Bueters T; Ploeger BA; Visser SA
    Drug Discov Today; 2013 Sep; 18(17-18):853-62. PubMed ID: 23665277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and the drug-target residence time concept.
    Dahl G; Akerud T
    Drug Discov Today; 2013 Aug; 18(15-16):697-707. PubMed ID: 23500610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development.
    Zhao L; Shang EY; Sahajwalla CG
    J Pharm Sci; 2012 Dec; 101(12):4367-82. PubMed ID: 23018763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates.
    Xu S
    Pharm Res; 2015 Nov; 32(11):3577-83. PubMed ID: 26108878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of pharmacokinetic and pharmacokinetic/pharmacodynamic modeling in drug discovery and development.
    Yu XQ; Wilson AG
    Future Med Chem; 2010 Jun; 2(6):923-8. PubMed ID: 21426110
    [No Abstract]   [Full Text] [Related]  

  • 18. Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs.
    Zhang R; Monsma F
    Expert Opin Drug Discov; 2010 Nov; 5(11):1023-9. PubMed ID: 22827742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling and Simulation of In Vivo Drug Effects.
    Lippert J; Burghaus R; Kuepfer L; Ploeger B; Schaller S; Schmitt W; Willmann S
    Handb Exp Pharmacol; 2016; 232():313-29. PubMed ID: 26578524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers and biomeasures: key enablers for pharmacokinetic-pharmacodynamic modeling in drug discovery and development.
    Agoram BM; van der Graaf PH
    Bioanalysis; 2012 Jun; 4(10):1143-5. PubMed ID: 22651555
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.